Express Scripts claims to be the No. 1 company in the mail order prescription business. In this video, Fool analyst Jim Mueller explains the Express Scripts business and the three things investors need to watch. Mail order prescriptions are attracting the attention of big pharma and generics alike, and how well Express Scripts penetrates these markets is critical to its future success.
Do lower costs = profits for your portfolio?
In 2011, a massive shift began. With the first of the baby-boomer generation reaching Medicare age, America's health care landscape was forever changed. Combine the aging population with the impact of Obamacare, and the need for innovative solutions for skyrocketing health care costs is as clear as ever. Express Scripts is part of that solution, and in this brand new premium report on the company, we clearly lay out the opportunity in front of this misunderstood stock. Claim your copy by clicking here now.
The article Express Scripts Investors: 3 Key Things You Should Be Watching originally appeared on Fool.com.
Austin Smith owns shares of Pfizer. Jim Mueller has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.